COPD

There are immense oppurtunities to transform the inhaler into a tool that tracks patients' use of asthma and COPD medications.

Kimberly Henderson, MD, JD, medical director for the Health Systems Alliance at CVS Health and regional medical director for MinuteClinic, discusses what pharmacists need to know about managing COPD.

The FDA has fast-tracked Cempra's solithromycin to treat community acquired bacterial pneumonia.

Follow up care with pulmonologist crucial to health outcomes.

Turnover from novel therapeutic target to model systems in clinical use remains a challenge.

Respiratory diseases affect millions worldwide and greatly burden the global health care system financially.

Medication will be used as an add-on maintenance therapy in patients aged 12 years and older.

Oxygen therapy use spikes since 2000.

Up to 13% of patients diagnosed with COPD under the GOLD criteria are actually misdiagnosed.

Up to 13% of patients considered to have chronic obstructive pulmonary disease (COPD) under current criteria were recently found to be misdiagnosed.

Generic Pulmicort Respules is approved for the treatment of asthma and to serve as prophylactic therapy in children aged 12 months to 8 years.

Here are new drugs for 2015 that pharmacists can expect to handle.

Everyday walking is the most commonly reported problematic daily activity for patients with chronic obstructive pulmonary disease (COPD).

Warfarin remains a cornerstone anticoagulant for a number of reasons that include its low cost at the pharmacy counter.

Premature aging of the lung cells plays a factor in pathogenesis.

Lung function and health status decreases across all levels of severity.

Patients with a burn injury were twice as likely to have been prescribed oxygen in the previous 90 days.

High hospital readmission rates plague the health care system.

Study finds many patients use propellant-based metered-dose inhalers incorrectly.

This Continuing Education activity is supported by educational grants from AstraZeneca LP and Boehringer Ingelheim Pharmaceuticals, Inc.

Respiratory diseases afflict a large portion of the global population and result in significant disease burden.

Here are new drugs for 2015 pharmacists can expect to handle.

Reslizumab targets a key cytokine involved in elevating levels of blood eosinophils.

Once-daily drug can be used to treat chronic bronchitis and emphysema.

The FDA today approved a new treatment for chronic obstructive pulmonary disease: tiotropium bromide and olodaterol inhalation spray.